# A Dose Escalation Study of SF1126, a PI3 Kinase (PI3K) Inhibitor, Given By Intravenous (IV) Infusion in Patients With Solid Tumors

> **NCT00907205** · PHASE1 · COMPLETED · sponsor: **Semafore Pharmaceuticals** · enrollment: 44 (actual)

## Conditions studied

- Advanced or Metastatic Solid Tumors
- Cancer
- Solid Cancers

## Interventions

- **DRUG:** SF1126

## Key facts

- **NCT ID:** NCT00907205
- **Lead sponsor:** Semafore Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-04
- **Primary completion:** 2011-01
- **Final completion:** 2011-04
- **Target enrollment:** 44 (ACTUAL)
- **Last updated:** 2013-06-13

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00907205

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00907205, "A Dose Escalation Study of SF1126, a PI3 Kinase (PI3K) Inhibitor, Given By Intravenous (IV) Infusion in Patients With Solid Tumors". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT00907205. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*